Retraction and republication—Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Author:
  • TMThe Editors of The Lancet Respiratory Medicine
    The Editors of The Lancet Respiratory Medicine

Abstract
No abstract available